MedTrace Logo

A Study of Guselkumab and Risankizumab in Healthy Participants and Participants With Psoriatic Arthritis

NCT05083078 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2022-07-26

No results posted yet for this study

Summary

The purpose of this study is to assess the tissue distribution of guselkumab and risankizumab in healthy participants (Part 1) and psoriatic arthritis (PsA) participants (Part 2 and Part 3).

Conditions

  • Arthritis, Psoriatic
  • Healthy

Interventions

DRUG

Guselkumab

Guselkumab will be administered subcutaneously.

DRUG

Risankizumab

Risankizumab will be administered subcutaneously.

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Research & Development, LLC Clinical Trial · Janssen Research & Development, LLC

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-11-04
Primary Completion
2022-07-01
Completion
2022-07-01
FDA Drug
Yes

Countries

  • Austria

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05083078 on ClinicalTrials.gov